241 related articles for article (PubMed ID: 34123955)
1. Epigenetic Regulation of Hepatocellular Carcinoma Progression through the mTOR Signaling Pathway.
Guo M; Li N; Zheng J; Wang W; Wu Y; Han X; Guo J; Chen W; Bai Z; Bai W; Wu J
Can J Gastroenterol Hepatol; 2021; 2021():5596712. PubMed ID: 34123955
[TBL] [Abstract][Full Text] [Related]
2. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.
Ferrín G; Guerrero M; Amado V; Rodríguez-Perálvarez M; De la Mata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070029
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development.
Cheng H; Xue J; Yang S; Chen Y; Wang Y; Zhu Y; Wang X; Kuang D; Ruan Q; Duan Y; Wang G
Oncotarget; 2017 Jul; 8(29):47984-47997. PubMed ID: 28624790
[TBL] [Abstract][Full Text] [Related]
4. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
6. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway.
Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N
Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347
[TBL] [Abstract][Full Text] [Related]
8. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma.
Lu C; Ning Z; Wang A; Chen D; Liu X; Xia T; Tekcham DS; Wang W; Li T; Liu X; Liu J; Qi H; Luo H; Du J; Ma C; Yan Q; Liu J; Xu G; Piao HL; Tan G
Cancer Lett; 2018 Nov; 436():139-148. PubMed ID: 30056112
[TBL] [Abstract][Full Text] [Related]
9. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma.
Rahmani F; Ziaeemehr A; Shahidsales S; Gharib M; Khazaei M; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
J Cell Physiol; 2020 May; 235(5):4146-4152. PubMed ID: 31663122
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma.
Wu Y; Zhang Y; Qin X; Geng H; Zuo D; Zhao Q
Pharmacol Res; 2020 Oct; 160():105195. PubMed ID: 32916254
[TBL] [Abstract][Full Text] [Related]
11. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
12. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.
Guerrero M; Ferrín G; Rodríguez-Perálvarez M; González-Rubio S; Sánchez-Frías M; Amado V; Pozo JC; Poyato A; Ciria R; Ayllón MD; Barrera P; Montero JL; de la Mata M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30650598
[TBL] [Abstract][Full Text] [Related]
13. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
Longerich T
Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
[TBL] [Abstract][Full Text] [Related]
14. Pivotal role of mTOR signaling in hepatocellular carcinoma.
Villanueva A; Chiang DY; Newell P; Peix J; Thung S; Alsinet C; Tovar V; Roayaie S; Minguez B; Sole M; Battiston C; Van Laarhoven S; Fiel MI; Di Feo A; Hoshida Y; Yea S; Toffanin S; Ramos A; Martignetti JA; Mazzaferro V; Bruix J; Waxman S; Schwartz M; Meyerson M; Friedman SL; Llovet JM
Gastroenterology; 2008 Dec; 135(6):1972-83, 1983.e1-11. PubMed ID: 18929564
[TBL] [Abstract][Full Text] [Related]
15. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma.
Vasuri F; Visani M; Acquaviva G; Brand T; Fiorentino M; Pession A; Tallini G; D'Errico A; de Biase D
World J Gastroenterol; 2018 Jul; 24(25):2647-2660. PubMed ID: 29991871
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
19. Molecular and functional genetics of hepatocellular carcinoma.
Yam JW; Wong CM; Ng IO
Front Biosci (Schol Ed); 2010 Jan; 2(1):117-34. PubMed ID: 20036934
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic deregulation of microRNAs: new opportunities to target oncogenic signaling pathways in hepatocellular carcinoma.
Yu Z; Cheng AS
Curr Pharm Des; 2013; 19(7):1192-200. PubMed ID: 23092339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
